of our study, a PICC line insertion team had already been in place in our NICU for many years, and central line insertion bundles were already in place. It did not appear that we had issues surrounding insertion technique. Hence, our intervention focused only on maintenance of central lines. Our intervention was more extensive, as our line team took over all aspects of line maintenance and care, not just dressing changes. Our line team handled all tubing changes, accessing of central lines and dressing changes at the onset. Ultimately, our line team also assumed the function of all medication administration through central lines.
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We were able to demonstrate a statistically significant decrease in our CLABSI rates from 141 infections per 12 141 line days to 109 infections per 27 042 line days, representing 205 CLABSIs avoided over time.
We agree that it is important to note that there is an increasing evidence in the literature that standardizing central line care by dedicated personnel or teams to maintain central lines results in lower incidence of CLABSI. The NICU size, resources and staffing options all impact how such teams are assembled and processes implemented. However, successes in a variety of NICUs, including ours, and the NICU in the Golombek study appear to demonstrate that central line maintenance teams should be generalizable across a spectrum of NICU settings. Reassuringly, the follow-up report from Juul and coworkers 1 about their phase I/II trial (IND12656) on early high-dose recombinant erythropoietin (rEpo) for neuroprotection in extremely low birth weight (ELBW) infants indicates no adverse long-term outcomes up to 36 months of age. This extends their initial report on the safety and pharmacokinetics in this study. 2 The assertion of the beneficial effects of rEpo, however, is apparently preliminary, likely because of incomplete data. Only 17 out of 25 survivors were examined, and the reason of the high drop-out rate (28%) remains unclear. Although infants in the study group were treated with different dosages of rEpo (3 Â 500, 1000 or 1500 iU kg À 1 per dose intravenously for the first 3 days, n ¼ 10 per group), analysis on the neurodevelopmental outcomes does not consider this aspect. Moreover, the number of examinations using the Bayley Scales of Infant Development at the age of 18 to 24 months was only 2 and 6 patients, respectively. A number of previous retrospective analyses point to better neurological outcomes in infants treated with rEpo (at dosages of X750 iU kg À 1 per week) for anemia of prematurity. [3] [4] [5] [6] Such treatment is necessary to consider in outcomes analysis, but information on the dosage of rEpo for treatment of anemia of prematurity given to 8 out of the 17 patients and their allocation to the three subgroups with different rEpo dosages is not provided. Of note, infants suffering from intraventricular hemorrhage (IVH) do fare better if initially treated with high-dose rEpo. This is in line with recent follow-up outcome measures in ELBW infants suffering IVH, who were treated with rEpo for the anemia of prematurity and examined at the age of 10 years. 6 Juul and coworkers 2 propose a large placebo-controlled trial on the neuroprotective efficacy of high-dose rEpo in preterm infants. Such a trial has been initiated (NCT00413946). After completing the pilot trial including 30 very preterm infants, 7 the study was extended to a multicenter trial within the Swiss Neonatal Network, recruiting a total number of 420 infants, treated with 3 Â 3000 U kg À 1 rEpo or placebo within 42 h after birth. Recruitment has been recently completed, but end-point neurodevelopmental outcomes measures (including Bayley Scales, magnetic resonance imaging) will last until the year 2014. One smaller phase II trial (NCT00589953; enrolling 22 preterm neonates, treated with 400, 800 or 1000 iU kg À 1 per day for 7 days) has been completed, but not reported yet. There are two more trials in which recruitment has been either suspended (NCT00910234) or not started yet (PENUT, NCT013778273). Thus, evidence of neuroprotective effects of rEpo in very preterm infants is still pending.
